AdoXLong monthly injection platform triples semaglutide half life in pigs in Adocia preclinical data
Adocia says its polymer linked AdoXL Sema lasted more than three times longer than semaglutide in pigs and four times longer in rats, with weight effects similar to semaglutide. No human data exist yet, and the company seeks partners.
What's new
Adocia released preclinical data at ObesityWeek 2026 showing its polymer linked semaglutide, AdoXL Sema, kept its activity and lasted three to four times longer than semaglutide in pigs and rats.
Why it matters
A monthly GLP 1 shot given with a thin needle pen could ease treatment, but all data come from cells and animals and none from people.
What's next
Adocia says it will move the platform toward clinical evaluation and prefers partnerships; no human trial date or partner has been named.
Adocia's AdoXLong monthly injection platform roughly tripled the half life of semaglutide in pigs and quadrupled it in rats, the Lyon company said in poster data released on 15 November for ObesityWeek 2026 in Washington. The French biotech says the results support testing a once monthly semaglutide shot in people. All of the data are preclinical. No human has received AdoXL Sema, the semaglutide version, and Adocia says it prefers to license the technology to drug makers rather than run the clinical program alone.
How the AdoXLong platform works
AdoXLong links a biocompatible polymer chemically to a peptide drug, according to Adocia. The company says the link stretches how long the drug circulates without changing how the peptide acts at its receptor. The goal is a monthly injection given with the same kind of ready to use pen and thin needle, 29 gauge or finer, that patients now use for weekly semaglutide or tirzepatide. Adocia lists GLP 1, GIP and amylin drugs, as well as dual and triple agonists such as tirzepatide, retatrutide and cagrilintide, as possible partners for the polymer. It filed a patent application on the technology in November 2025. If granted, Adocia says, that patent would protect the platform worldwide until 2046.
The business case rests on two arguments from the company. First, Adocia says a monthly form could reduce the high share of patients who stop GLP 1 treatment within the first year, and with it the loss of benefit that follows. That is a hypothesis; no trial has yet tested whether monthly dosing improves persistence. Second, the platform can be applied to older peptides as well as new ones. Adocia notes that semaglutide has been off patent in some territories since March 2026, so a modified version could carry fresh intellectual property. The company, listed on Euronext Paris with about 80 staff, also runs platforms for stabilizing peptide formulations, oral peptide delivery and cell transplantation.
What the AdoXL Sema poster reports
The poster is titled "AdoXLong: A Long-Acting Peptide Platform Enabling Once-Monthly Administration of Incretins." In laboratory tests, AdoXL Sema kept the potency and efficacy of plain semaglutide at its receptor, Adocia said. Its activity dropped when human serum albumin was added, which the company reads as a sign of tight binding to albumin, the blood protein that also carries semaglutide. After an injection under the skin in rats, the half life was 32 hours, more than four times that of semaglutide. In farm pigs, the half life was 153 hours after an intravenous dose and 159 hours after a dose under the skin, more than three times semaglutide's. Bioavailability under the skin was above 90%.
In farm pigs, the half life was 153 hours after an intravenous dose and 159 hours after a dose under the skin, more than three times semaglutide's.
Adocia also tested weight effects in animals. AdoXL Sema reduced body weight gain to a similar degree as semaglutide, with a maximum drop of about 5% to 6% from baseline, according to the release. That result shows the modified drug still works, but it does not show any advantage in weight loss, and the release does not compare it with a monthly regimen. The company's semaglutide comparison point is a half life of 46 hours, taken from a patent cited in a footnote. Half lives in rats and pigs do not translate directly into human dosing intervals. Semaglutide itself is already given once a week in people, so the platform would need to stretch the human dosing interval about four fold to reach a monthly shot.
Retatrutide results and how they compare
Adocia also released new laboratory data on AdoXL retatrutide, built on Eli Lilly's investigational triple agonist. The modified molecule kept its activity at all three of its target receptors, GLP 1, GIP and glucagon, the company said. Adocia expects it to circulate longer in the body than plain retatrutide, as AdoXL Sema did, but it has not yet shown that in animals. The table lists the figures in the release, with the model behind each, since every number comes from cell or animal work and none comes from people. Retatrutide itself has not been approved, and Adocia did not say whether Lilly is involved in the work.
| Test | Model | Reported result |
|---|---|---|
| Receptor potency of AdoXL Sema | Cell assays | Preserved against semaglutide |
| Half life under the skin | Rats | 32 hours, over 4 times semaglutide |
| Half life intravenous and under the skin | Farm pigs | 153 and 159 hours, over 3 times semaglutide |
| Bioavailability under the skin | Farm pigs | Above 90% |
| Body weight | Animal study | About 5% to 6% maximum drop, similar to semaglutide |
| Receptor activity of AdoXL retatrutide | Cell assays | Preserved at all three receptors |
Adocia is not alone in chasing monthly GLP 1 dosing. Camurus is already testing a monthly semaglutide depot in people with obesity or overweight, as covered in the Camurus LUNAR 2 trial report. Pfizer is also running monthly GLP 1 trials with its candidate berobenatide. Those programs have reached human testing, so the AdoXLong monthly injection approach is at an earlier stage than its rivals. Its claimed difference is the user experience. Adocia says the shot would be given with the same kind of thin needle pen patients use today for weekly drugs. That claim, like the semaglutide half life gain seen in animals, will need testing in people before it counts as an advantage.
What Adocia plans next
Chief executive Olivier Soula said the company intends "to continue its development toward clinical evaluation, while favoring partnerships with pharmaceutical companies to apply AdoXLong to their peptides." Adocia did not give a date for a first human study, name a partner or say what such a study would cost. Its own risk statement in the ObesityWeek release points investors to short and medium term working capital needs and the uncertain outcome of research. That matters because platform deals often depend on clinical proof that the company has not yet produced. The poster is posted on the company website, according to the release.
Several questions remain open. The release gives no data on how the polymer is cleared from the body, whether it builds up with repeated monthly dosing, or whether it changes the immune response to the drug. It also reports no repeat dose toxicology. Those points usually decide whether a long acting carrier can enter human trials. The AdoXLong monthly injection data show that the modified semaglutide keeps its activity and lasts longer in two animal species. They do not yet show a monthly profile in people. More industry moves in peptide delivery are tracked on the Peptide Zone industry desk.
Conclusion
The AdoXLong monthly injection platform extended semaglutide's half life severalfold in rats and pigs while keeping its activity, and an early retatrutide version held up in cell tests. These are company reported preclinical results from a poster. Whether the polymer delivers a safe once monthly shot in people, and whether a partner will pay to find out, remain the questions that decide its value.